| Popis: |
Background Hepatocellular carcinoma is characterized by high morbidity and mortality, poor prognosis and many complications. Hepatic arterial chemoembolization (TACE) is the main treatment for patients with advanced hepatocellular carcinoma. To investigate the effect of Lenvatinib and bevacizumab on hepatocellular carcinoma after hepatic arterial chemoembolization. Method 30 patients with primary hepatocellular carcinoma treated by hepatic artery chemoembolization were selected. The observation group was injected with bevacizumab (5 mg/ kg) into the blood vessels supplying tumor, Lenvatinib mesylate capsules were given orally. SPSS 25.0 was used for statistical analysis. χ2 test ,analysis of variance and T test were used. Results The levels of AFP, Angiotension Converting Enzyme (ACE), AST and albumin in the observation group was significantly lower than in the control group. In the observation group, the number of cases with decreased platelet after treatment was 11, which was significantly higher than that in the control group. The pain relief and clinical efficacy of the observation group after treatment were better than the control group. Conclusions After hepatic arterial chemoembolization, Lenvatinib and bevacizumab can effectively improve the serum AFP, ACE, AST, albumin and platelet levels, improve liver pain. |
